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Abstract
Attention deficit hyperactivity disorder (ADHD) is the most commonly diagnosed neurobehavioural disorder in
childhood, affecting over 5% of children worldwide. As well as the core symptoms of inattention, hyperactivity and
impulsivity, patients often exhibit learning difficulties and impairment in social functioning. The frequency of
referral is higher for boys than for girls (about 2:1), and girls are generally older at the time of referral.
Pharmacological therapy is considered the first-line treatment for patients with severe ADHD and severe
impairment. Stimulant medications are licensed in the UK for the management of ADHD in school-age children
and young people, and are effective in controlling ADHD symptoms.
While immediate-release preparations of methylphenidate (MPH) have proven effective in the treatment of ADHD,
there are a number of problems associated with their use, most notably compliance, stigma and medication
diversion. Modified release preparations are now available that overcome the need for multiple daily dosing, and
which offer different MPH release profiles, thereby enabling the physician to match the medication to the patient’s
particular requirements.
This review describes the diagnosis, referral and treatment pathways for patients with ADHD in the UK and the
practical considerations when initiating pharmacological treatment. The clinical experience of treating ADHD with a
modified-release MPH preparation (Equasym XL
®) is illustrated with case studies.
Introduction
Attention deficit hyperactivity disorder (ADHD) is the
most commonly diagnosed neurobehavioural disorder in
childhood; a recent meta-regression analysis estimated a
worldwide prevalence of 5.29% among children and ado-
lescents [1]. It is characterised by inappropriate levels of
inattention, hyperactivity and impulsivity, and often
accompanied by comorbid symptoms such as aggressive
behaviour, depressive mood, anxiety and tics [2].
Furthermore, learning difficulties [3] and impairment in
social functioning [4] are frequently observed in patients
with ADHD. The symptoms of ADHD decline with
increasing age, and although most patients with ADHD
no longer meet the full criteria for the disorder when
they reach adulthood, up to 50% of childhood cases
continue to show clinically relevant symptoms during
adolescence and adult life [5].
In the UK, patients with suspected ADHD, identified
through concerns from school (teachers, special educa-
tional needs coordinators and educational psychologists)
or family members, are brought to the attention of the
general practitioner (GP) via parents. Children are then
referred for further specialist assessment for ADHD.
The referral pathway varies in different parts of the
country, with paediatricians carrying out the diagnostic
assessment in some areas and child psychiatrists in
others; some centres provide a joint service involving
both paediatricians and child psychiatrists.
Children referred to their GP usually present with
concerns of inattention, hyperactivity and impulsivity.
Symptoms impact on their academic achievements and
social interaction at school; home life can also be very
difficult, as children with ADHD are constantly active
and demanding, which tends to cause conflicts with
their families. The frequency of referral is higher for
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any medium, provided the original work is properly cited.boys than for girls (about 2:1), and girls are generally
older at the time of referral. This is probably because
girls are more likely to have the predominantly inatten-
tive subtype of ADHD [6], which, because the symptoms
are less striking, is often identified only when poor aca-
demic performance is noticed. Symptoms also vary with
age and may be less obvious, but equally impairing, in
older adolescents. Notable risk factors for developing
ADHD include family history of ADHD [7], preterm
birth and smoking or drinking during pregnancy [8].
Pharmacological therapy is considered the first-line
treatment for patients with severe ADHD and severe
impairment [9]. Stimulant medications, such as methyl-
phenidate (MPH) and dexamfetamine, and the non-sti-
mulant, atomoxetine, are licensed in the UK for the
management of ADHD in school-age children and
young people, and are effective in controlling ADHD
symptoms [9]. The guidelines produced by the UK
National Institute of Clinical Excellence (NICE) [9]
recommend MPH as the first-choice medication for
patients without comorbidities, for those with comorbid
conduct disorder and when tics, Tourette’ss y n d r o m e ,
anxiety disorder and stimulant misuse or risk of stimu-
lant misuse are present; however, MPH should be used
with caution in such patients. Although the mechanism
of action is not completely understood, MPH is known
to be associated with an increase in dopamine and nore-
pinephrine levels in the extraneuronal space, probably
owing to reuptake inhibition. This is thought to improve
neurotransmission and to mediate the beneficial effects
of MPH on ADHD symptoms [10]. MPH is primarily
metabolised by de-esterification to ritalinic acid, which
is pharmacologically inactive; therefore, MPH has a low
absolute bioavailability, and a short half life (2-3 h) and
duration of action [11-13].
Immediate-release formulations of MPH (MPH-IR)
have been used since the 1960s to control ADHD symp-
toms. With MPH-IR, peak plasma concentrations and
optimum behavioural effects are reached approximately
1.5-2.0 h after administration [14]. The limited duration
of action means that most children require two or three
daily doses to maintain control of ADHD symptoms
throughout the day [15]. However, medication doses
given during the school day can cause compliance issues
and problems related to privacy, stigmatisation by class-
mates, accountability of the school administration and
potential abuse or diversion due to availability of the
medication in school [10,16]. To eliminate the need for
multiple daily doses, modified-release MPH (MPH-MR)
formulations have been designed which combine IR and
delayed-release (DR) components, and produce a rapid
onset of therapeutic effect while having a sufficient
duration to eliminate the need for additional dosing.
MR formulations avoid the oscillations in plasma
concentration seen with multiple dosing of MPH-IR, but
at the same time present a biphasic profile rather than a
flat profile, preventing the development of acute toler-
ance [17]. MPH-MR formulations approved in the UK
are listed in Table 1. The pharmacokinetic (PK) profile
over time of these formulations is distinct, and their
effect on behaviour parallels the blood concentration of
MPH. MPH-MR 50:50 (Medikinet XL
®) and MPH-MR
30:70 (Equasym XL
®) have been shown to be equivalent
to twice-daily MPH-IR [18,19], while MPH-OROS (Con-
certa XL
®) is equivalent to MPH-IR, three times daily,
although at a 20% higher dose [20]. Several comparative
studies between MPH-MR products have shown the
relative efficacies over different periods of the day,
depending on the release profile [21-23]. Having differ-
ent MPH-MR proportions with differing release profiles
allows tailoring of treatment to each patient, depending
on the desired profile of symptom control throughout
the day. This review focuses on the practical and clinical
experience with the MR preparation MPH-MR 30:70 in
a UK paediatric ADHD clinic.
Practical considerations for initiating MPH treatment
At the start of treatment with any MPH formulation,
careful dose titration is necessary. IR and long-acting
formulations of MPH can both be used to initiate treat-
ment of ADHD [24-26]. In some cases, IR preparations
are slowly titrated by weekly increments of 5-10 mg/day
according to tolerability and the degree of efficacy
observed, up to a maximum daily dose of 60 mg; IR pre-
parations are taken in divided doses, usually at breakfast
and lunch [24]. Some patients are stabilised on MPH-IR
and then switched to a corresponding dose of MPH-
MR. However, it is commonly accepted practice now in
most areas of the UK to initiate ADHD therapy directly
with the lowest available dose of MPH-MR when this
medication has been chosen as the treatment of choice.
The dose should be incremented slowly, every 1-2
weeks, until an effective dose is reached. Children as
young as 6 years old can have treatment initiated with
the capsule formulations of MPH-MR, as these can be
opened and the contents given in soft food [24,26].
Table 1 Extended-release preparations of
methylphenidate currently available in the UK
Brand
name
UK marketing
company
Technology IR:DR
ratio
Medikinet
XL
Flynn Pharma Ltd Multiparticulate bead
system
50:50
Equasym
XL
Shire Pharmaceuticals
Ltd
Multiparticulate bead
system
30:70
Concerta
XL
Janssen-Cilag Ltd Osmotic release oral
system
22:78
DR = delayed release; IR = immediate release.
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satisfactory symptom control at the lowest total daily
dose and with the fewest adverse events (AEs) should be
employed. In cases where treatment effects wear off too
early, patients can be given an extra dose of MPH-IR in
the late afternoon or early evening if needed [24,26]; for
example, for doing homework or maintaining focus dur-
ing after-school activities. However, caution should be
applied in children with significant appetite suppression
or sleep problems, as the additional MPH-IR may nega-
tively affect them.
The choice between treatment options should be
determined on an individual basis, with particular con-
sideration of the requirement for symptom control in
the latter part of the day. MPH treatment is generally
well tolerated by patients and severe AEs are rare.
Increased insomnia, other sleep-related problems and
reduced appetite are common, and there is some evi-
dence for increased levels of emotionality, social with-
drawal, nausea and stomach aches, although it is not
clear which of these AEs are related to pre-existing pro-
blems associated with ADHD prior to treatment [27].
Furthermore, treatment tolerability does not appear to
be predictable on the basis of patients’ clinical charac-
teristics [27].
Long-term side effects of MPH include weight loss
from reduced appetite and reduction in height velocity
[28]; the magnitude of such effects has been controver-
sial for many years [29]. The cause of the reduction in
height velocity is not entirely clear [30]. In some cases,
i ti st h o u g h tt h a ti tm a yb es e c o n d a r yt ot h ee f f e c to f
MPH on weight [30]. It has also been suggested that
ADHD itself may be associated with temporary deficits
in height gain during mid adolescence, supporting the
hypothesis that this effect could be a consequence of the
disease rather than its treatment [31]. The height of
most children normalises with increased age and most
achieve normal adult height; however, in a few cases
where height is significantly affected during ongoing
monitoring, children should be referred to a paediatric
endocrinologist to rule out any undiagnosed growth
problems.
Equasym XL
This MPH-MR 30:70 formulation of MPH contains a
30:70 ratio of IR to DR MPH by weight [17]. It uses a
multiparticulate bead delivery system in a capsule, in
which each bead acts as a drug reservoir; a distinct
a d v a n t a g eo ft h i ss y s t e mi st h a tc a p s u l e sc a nb es w a l -
lowed whole, or their contents can be sprinkled onto a
small amount of apple sauce, without altering the bioa-
vailability of the MPH [32]. This may be helpful in very
small children or those with swallowing or gastrointest-
inal issues.
The efficacy of MPH-MR 30:70 in children with
ADHD has been demonstrated in three 3-week rando-
mised, double-blind studies: a placebo-controlled non-
inferiority study compared with a twice-daily IR formu-
lation [19] and a parallel-group, placebo-controlled clini-
cal trial [33], both conducted in a community setting,
and a comparative, laboratory classroom study, (Com-
parison Of Methylphenidates in an Analog Classroom
Setting (COMACS)) [23], with several secondary ana-
lyses [27,34-37]. Study details are shown in Table 2.
These trials show that MPH-MR 30:70 is an effective
and well tolerated once-daily treatment for ADHD
[19,27,33-37]. However, the COMACS secondary ana-
lyses also made it clear that different patients respond in
different ways to MPH-MR formulations [35,36]. This
heterogeneity of response is an important consideration
when deciding treatment options for children with
ADHD. COMACS also showed that parents and tea-
chers assess symptoms differently, highlighting the need
for comprehensive assessment measures [37]. It should
also be noted that clinical trial data represent the aver-
age values from variable populations. Therefore, for
each individual, the most rational initial choice (based
on clinical trial results) might not be the best treatment.
Reliable, cost-effective, predictive factors that can be
used in everyday clinical practice are needed.
Challenges in clinical practice
In the specialist ADHD clinic in East and North Hert-
fordshire, UK, assessment is by use of the P4 screening
questionnaire, which is a 33-item screening question-
naire based on the Diagnostic and Statistical Manual,
fourth edition (DSM-IV) criteria and which assesses the
core symptoms of ADHD: concentration, hyperactivity
and impulsivity. The P4 was designed by one of the con-
sultant child psychiatrists in the team and has been in
use for 15 years as one of the tools available for screen-
ing the core symptoms of ADHD. The questionnaire
has shown good correlation with information received
from school and home in identifying children with
ADHD, although it has not been validated in population
studies. The diagnostic assessment in our unit involves:
(1) diagnostic interview with the parent/carer and the
child/young person in the clinic (the interview lasts on
average 1 h). (2) School observation of the primary
school child to assess for core symptoms of ADHD.
This observation is usually carried out by the ADHD
nurse specialist, using a structured form. The process
includes observation of the child in the playground to
observe social interaction with peers, observation of the
child during lessons to check for impulsive and inatten-
tive behaviours as well as overactivity, and a review of
the child’s completed class work. (3) Review of the
screening questionnaires (P4) sent to home and school.
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subject teachers for the secondary school child.
After the conclusion of the diagnostic assessment by
the paediatrician, the child psychiatrist, or both, a dis-
cussion is held with the parents and the young patient
about the diagnosis and the different types of manage-
ment options available. Information on where to access
further parenting courses in managing the child’sb e h a -
viour and psychoeducational materials are made avail-
able. When pharmacological therapy is recommended,
the various types of medication available and their risks
and benefits are discussed, and it is general practice to
make this as visual as possible for the child and his/her
parents by showing them dummy tablets of the pro-
posed medication. Each of the child’s difficulties is con-
sidered, to evaluate areas of particular concern. It is
worth noting that the majority of parents accept phar-
macological treatment for their children when indicated,
although it is worth spending some time explaining how
the medication works and allowing them to ask any
questions they might have. Families also have further
access to the ADHD nurse who sees the families after
the initial clinic appointment and who discusses further
questions that families may have and provides informa-
tion on additional resources needed. Consent is usually
obtained from the families to contact the school, and
information on managing ADHD within the school is
also forwarded to the class teacher.
In primary school children, who carry out most of
their schoolwork in school with little requirement for
homework after school, preparations such as MPH-MR
30:70 are very useful. The child feels better as all the
medication is taken at home before leaving for school
and there is a lower risk of poor compliance, as parents
ensure the child takes the medication. In addition, there
is a lower risk of stigmatisation in school.
Table 2 Clinical studies assessing the efficacy of MPH-MR 30:70
Parameter Information
Study Greenhill et al., 2002 [33]
Type Community setting. Multicentre, placebo-controlled, USA.
Population
characteristics
6-16 years old, mild ADHD
Interventions Placebo (163), MPH-MR 30:70 (158)
Dose and duration 20-60 mg/day, titrated to optimum efficacy (3 weeks)
Outcome measures Teacher and Parent Conners’ Global Index, CGI-S, CGI-I
Conclusions Equasym XL administered once daily in the morning was well tolerated and significantly more effective than placebo in
controlling ADHD symptoms throughout the school day. Symptom control was achieved in the morning and afternoon.
Study Findling et al., 2006 [19]
Type Community setting. Non-inferiority, Australia, Canada and USA.
Population
characteristics
6-12 years old, ADHD
Interventions Placebo, Ritalin (IR), MPH-MR 30:70
Dose and duration According to prestudy MPH regimen. Equasym XL, 20-60 mg/day; Ritalin, 10-30 mg twice daily (3 weeks).
Outcome measures Teacher’s and parent’s IOWA Conners’ Rating Scale
Conclusions Equasym XL once daily was statistically non-inferior to Ritalin twice daily in the treatment of school-age children with
methylphenidate-responsive ADHD. Both Equasym XL and Ritalin were superior to placebo in controlling ADHD symptoms,
and were well tolerated.
Study Swanson et al., 2004 [23]
Type Laboratory-classroom setting. Double-blind, three-way, crossover study, USA.
Population
characteristics
6-12 years old, confirmed ADHD
Interventions MPH-MR 30:70, Concerta XL
Dose and duration Assigned to low (20 or 18 mg/day), medium (40 or 36 mg/day) or high (60 or 54 mg/day) dose according to prestudy MPH
dose. Crossover design, so all patients received both active agents and placebo for 7 days each throughout a 3-week period.
Outcome measures SKAMP Rating Scale, PERMP
Conclusions There were statistically significant differences between the efficacy of Equasym XL and Concerta in children with ADHD in the
laboratory school setting. As predicted by the PK/PD model, clinical superiority at any time point was achieved by the
formulation with the highest expected plasma methylphenidate concentration.
ADHD = attention deficit hyperactivity disorder; CGI-I = Clinical Global Impression-Improvement; CGI-S = Clinical Global Impression-Severity; IOWA = inattention/
overactivity with aggression; IR = immediate release; PERMP = Permanent Product Measure of Performance; SKAMP = Swanson, Kotkin, Agler, M-Flynn and
Pelham.
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the East and North Hertfordshire ADHD service. This
nurse will usually follow-up, by telephone, with the
family, 1-2 weeks after the medication regimen has
started in order to assess the child’sr e s p o n s et ot h e
medication, and to start titration to the therapeutic
dose. All follow-up visits use a structured pro forma
that is used to review the core symptoms of ADHD and
side effects of medication (in children treated with med-
ication). The instrument also captures information on
progress with learning and any emotional concerns. A
summary of discussions with the family is maintained,
including an action plan and plan for reviews.
Children started on medication are usually seen in the
clinic after 1 month, and the optimal dose is determined.
They are subsequently followed up on a 6-monthly basis
if their symptoms are stable, and their height, weight and
blood pressure are monitored; this is sometimes per-
formed by the ADHD nurse specialist in the nurse-led
clinic. Parents are instructed to contact the ADHD team
(nurse specialist or clinician) if they have any concerns
that require an earlier review. Side effects are usually
transient and tend to subside. Children treated for
ADHD with more complex issues, who have poor toler-
ance to medication or who experience side effects are
usually seen more frequently, and follow-up varies from
monthly to 3-monthly. There is flexibility within the ser-
vice to see children earlier if the need arises. The struc-
tured pro forma described above is used during all
follow-up visits, including telephone consultations.
It is useful to have an up-to-date progress report from
the school for the follow-up visits. This helps to monitor
progress on the core symptoms of ADHD and also to
find out about school, home and sibling progress.
Where there is a lack of response to the medication, it
is advisable to explore possible reasons through a dis-
cussion with the child, rather than stop treatment
abruptly.
Children who are stable on the 8-h preparation of
MPH-MR 30:70 can be prescribed an additional MPH-
IR dose in the evening when they make the transition to
secondary school. This prevents changing the prepara-
tion to an entirely different one, particularly when it has
been well tolerated, and extends symptom control to
allow management of homework or other after-school
activities.
Managing side effects
The majority of children respond well to long-acting
MPH, although a few patients show appetite suppression
and other side effects such as emotional concerns, anxi-
ety, mood changes and tics. In some cases, temporary
withdrawal of long-acting MPH may be necessary to see
if the side effects subside.
To manage poor weight gain, children may receive
additional calories in the form of milk shakes or addi-
tional foods recommended by dieticians. With the 8-h
MPH preparation there is usually a catch-up period in
the evenings, when the medication effect wears off and
children eat normally. Children are usually advised to
eat a substantial breakfast before taking their medication
and most are able to eat a healthy portion of food in the
evening.
Children with reduced height velocity may need to
discontinue the medication temporarily if their height
velocity continues to drop. As mentioned above, referral
to a paediatric endocrinologist will determine whether
there is an underlying growth problem.
Headaches and abdominal pain usually improve after
the first week of treatment; however, if they persist,
analgesia can be given to relieve the symptoms. Emo-
tional lability also usually improves with time; if it per-
sists, the dose of the medication should be reviewed.
Illustrative case studies of patient-tailored treatment with
MPH-MR 30:70
Case study 1
Patient 1, age 14 years, presented with behavioural diffi-
culties at home and school, and was first seen by clini-
cians following referral to the ADHD clinic at the age of
10 years. Concerns raised included challenging beha-
viour, impulsive behaviour, hyperactivity and fidgeting.
Patient 1 lashed out very easily and struggled to calm
down when he had an outburst; he had many outbursts
at school, which made his peers wary of him, and was
worried about his social skills.
Patient 1 had some initial risk factors. He was born
following a full-term pregnancy, weighed 3.5 kg and was
in the special care baby unit for 2 days as a result of
low blood sugar. He was the second child born to his
mother. There was a history of domestic violence from
patient 1’s father, and his mother also had a history of
psychiatric illness. Patient 1 had normal motor develop-
ment milestones, but his speech and language develop-
ment were delayed, and he also suffered from sleep
difficulties.
Patient 1 was diagnosed with ADHD at age 6.5 years
in a different county but had not been treated with
medication. Patient 1 and his mother then relocated to
a different county and a further review of his symptoms
was requested following increasing concerns regarding
his behaviour at home and at school. The assessments
consisted of a diagnostic interview by clinicians and a
screening of the information received from home and
the school. It was confirmed that patient 1 had ADHD
combined type.
Patient 1 started treatment with MPH-OROS, but sig-
nificant symptom control was not achieved; his dosage
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dose of MPH-OROS (72 mg) but he felt that the medi-
cation effect wore off easily and also affected his appe-
tite. Patient 1’s medication was subsequently changed to
50 mg/day MPH-MR 30:70, and then titrated up to 60
mg/day, which he tolerated better than MPH-OROS. He
made significant improvements: his concentration and
his school grades improved (he also moved to a smaller
school). Patient 1’s weight, height and blood pressure
were normal for his age.
Patient 1 is now making good progress in school and
is generally happier, as confirmed by school reports, par-
ental reports of school progress and by the medication
monitoring document. He has also been able to form
friendships. He is being followed up every 6 months in
the ADHD clinic.
Case study 2
Patient 2 was referred at age 5.5 years, following review in
a child development centre, for concerns relating to poor
concentration, impulsive behaviour and poor interaction
in school. Patient 2’s difficulties first became apparent
when she was in preschool, where she required one-to-
one support. She had problems with balance and motor
skills, and walked with her feet turned in. She also had
sleep difficulties and was very restless during sleep. At
nursery, she had been functioning at an average level.
Patient 2’s behaviour had a significant impact on the
whole family; she had defiant and attention-seeking
behaviours.
Patient 2 was born 1 week after her due date of birth;
there were no concerns following her birth and she had
been in good health. There was a family history of psy-
chiatric illness in her mother’sg r a n d f a t h e r ,a sw e l la sa
history of hyperactivity and defiant behaviours in patient
2’sc o u s i n .P a t i e n t2 ’s clinical examination showed joint
laxity but her neurological examination was normal.
Patient 2 had a diagnostic assessment for ADHD and
was found to have very high scores for inattention,
hyperactivity and impulsivity, leading to a diagnosis of
ADHD combined type with comorbid oppositional defi-
ant disorder. ADHD management was discussed with
the family, and her parents’ decision was to try beha-
vioural strategies at home and at school, and review
patient 2’s behaviour and progress in 1 year.
At 1 year later, her sleep problems had worsened; she
was started on melatonin to help with her sleep, which
improved slightly, but continued to have significant
ADHD symptoms that had an impact on her learning.
Patient 2 was started on MPH-MR 30:70 10 mg to help
control ADHD symptoms during the school day and her
dose was gradually titrated to 30 mg once daily. Patient
2’s ADHD and comorbid symptoms improved, including
her concentration, her play and social skills, her rela-
tionship with friends, parents and sibling, and her sleep
difficulties. Her dyspraxia and motor difficulties also
improved.
Patient 2 has made good progress on MPH-MR 30:70
30 mg and has had no side effects; she continues to
have 2 mg of melatonin at night to improve her sleep
pattern. She is being followed up on a 6-month basis.
Case study 3
Patient 3, age 10 years, was referred at age 8 years with
significant concerns about her behaviour in school. She
was very talkative in class, fidgety and disruptive.
Patient 3 was born following a normal pregnancy and
had no problems after birth. She was an only child and
was brought up following a very strict routine. Her
developmental milestones were advanced, and she had
many falls and emergency-room visits in the first few
years of life. She also struggled significantly with learn-
ing and was found to have dyslexia. Although her dys-
lexia was well supported, she struggled continuously
with her concentration; she frequently got into trouble
in school and this caused significant difficulties for her
parents, whose work life was constantly disrupted by
calls from the school.
Patient 3’s parents had her referred for further assess-
ment for ADHD. The positive and problem profile ques-
tionnaire (similar to the strengths and difficulties
questionnaire) was sent to her parents and the school,
and school observation was arranged by the ADHD
nurse specialist. Patient 3 showed borderline scores for
all the core symptoms of ADHD.
Patient 3 was initially started on MPH-IR, 10 mg twice
daily, following her parents’ request for a short-acting
preparation, to help them monitor her response during
medication titration. The effect of the medication wore
off quickly so her symptoms were not fully controlled.
Her medication was then switched to MPH-MR 30:70, 30
mg once daily, to which she responded better. Patient 3
was satisfied with the once-daily dosage of MPH-MR
30:70 as she did not need to take medication in school
and be different from her peers. Patient 3’s relationship
with her peers improved, and although she had slight
appetite suppression whilst on the medication, she was
able to have a normal evening meal with her family when
she got back home, after the medication effect wore off.
Patient 3 has made good progress on MPH-MR 30:70
and her symptoms are well controlled during the school
day. She is due to start secondary school education and
the plan is for patient 3 to continue taking MPH-MR
30:70 for the school day, with the option to add an
MPH-IR preparation for the late afternoon when she is
required to concentrate on homework. Patient 3 is satis-
fied with continuing the medication in secondary school.
Case study 4
Patient 4, age 10 years, had a long history of poor con-
centration, and defiant and challenging behaviour. She
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and had a history of delay in all areas of her develop-
ment; she walked late, talked late (age 3) and found
mainstream schooling very challenging.
Patient 4’s parents separated when she was 4 years
old, and a shared contact arrangement with both par-
ents was agreed. After the separation of her parents,
patient 4’s behaviour became increasingly challenging.
She found it difficult to settle in mainstream school and
made little progress in her learning; she was, therefore,
transferred to a special school for children with moder-
ate learning disabilities. Patient 4’s behaviour continued
to deteriorate in the special school. She was very impul-
sive, defiant and constantly fidgety; she lashed out fre-
quently at teachers and other children, and had a very
poor concentration span. She had a structured beha-
vioural management plan in school as well as a period
of monitoring. However, although her behaviour
improved slightly, she made no progress in her learning,
as reflected by her poor school grades and her teachers’
reports, and she continued to have problems with con-
centration and constant fidgeting.
Patient 4 was assessed for ADHD and her symptoms
met the diagnostic criteria for ADHD with comorbid
oppositional defiant disorder. She was started on a low
dose of MPH-IR and showed a slight improvement but
had significant rebound symptoms and several emo-
tional side effects. She was moody, very tearful and her
behaviour was of concern at home and at school. Her
medication was then changed to MPH-MR using MPH-
MR 30:70. She showed a slight improvement for a few
weeks at a dose of 20 mg/day but had significant pro-
blems with poor appetite and poor sleeping patterns;
according to her parents, she was also more aggressive
on MPH-MR 30:70. The dose was reduced to 10 mg
without any appreciable reduction of side effects. As she
did not tolerate even small doses of MPH, MPH-MR
30:70 was discontinued and clonidine (starting at 25 μg
once daily for 1 week, titrated up to 25 μg twice daily
for 1 month), a non-stimulant preparation, was started
to help with ADHD symptoms. Although clonidine is
not currently approved in ADHD, evidence suggests it
m a yh a v es o m eb e n e f i t[ 3 8 ] .A f t e r1m o n t ha t2 5μg
twice daily, clonidine was also discontinued as patient 4
still showed many side effects and appeared subdued,
very moody and tearful on medication.
Patient 4 had all medication discontinued, and a per-
iod of monitoring was carried out with more beha-
vioural support and one-to-one management. She
continued to struggle with poor attention and concen-
tration, showed a lack of progress with learning and
exhibited high levels of anxiety. A meeting of health,
education and social services professionals was held to
address patient 4’s needs. She was reassessed by the
doctor and diagnosed with ADHD, comorbid opposi-
tional defiant disorder and additional comorbidities,
such as anxiety symptoms and learning difficulties. She
was also assessed for autistic spectrum disorder but did
not meet the diagnostic criteria.
Patient 4 was trialled on atomoxetine and given access
to a nurse support service for patients on this medica-
tion, run by an independent provider. She was started
on 10 mg once daily for 2 weeks, titrated to 18 mg once
daily for 2 weeks, and then maintained on 25 mg once
daily thereafter. Titration was performed slowly, with
close monitoring. Patient 4 showed a significant
response to atomoxetine: her core ADHD symptoms
improved, she was less anxious and her appetite and
sleep improved. She still has some residual symptoms of
impulsivity but, overall, she has made progress through
a combination of atomoxetine and behavioural
strategies.
Conclusions
The early identification of ADHD symptoms in children
is essential to prevent the complications that arise from
late diagnosis. Children with risk factors for ADHD
(such as prematurity, low blood sugar, difficulties
around the time of birth with hypoxic brain injuries or
infections, and children who develop difficulties with
concentration and learning) [39-41] need to be screened
and assessed for ADHD. Sleep difficulties are also com-
mon in children with ADHD [42] and may be an early
sign in some cases. Sleep problems in children who also
have a diagnosis of ADHD may improve upon treatment
with medication [43].
Treatment with MPH-MR 30:70 prevents disruption
in the child’s school day programme by removing the
need for a lunchtime medication dose administered in
school. Parents who have doubts about medication
treatment and concerns about the child taking medica-
tion in school are more likely to accept treatment with
a flexible once-a-day preparation such as MPH-MR
30:70.
Children treated with MPH-MR 30:70 can have pro-
blems with appetite suppression, but as the effect wears
off in the evening, the child is usually able to eat a nor-
mal evening meal, which prevents weight loss in most
children.
Some children with learning difficulties and ADHD
can have a poorer response to MPH compared with
children without comorbidities. In these cases, the side
effects of MPH-MR 30:70 can be seen with very small
doses of MPH. Children with poor response to MPH-
MR 30:70 and other MPH preparations should have
their symptoms re-evaluated to rule out comorbidities
such as anxiety disorder and autistic spectrum disorder,
which may account for the poor response.
Takon Annals of General Psychiatry 2011, 10:25
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Page 7 of 9Providing adequate support for children treated with
MPH-MR 30:70 is essential to ensure compliance with
treatment.
Consent
Formal consent has been obtained by the Author for all
cases reported in the article.
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